CARLSBAD, Calif.—SynergEyes, Inc., the high Dk hybrid contact lens manufacturer, announced the closing of $13.3 million in Series C financing to fund the development and clinical trials for next-generation hybrid contact lens products and to expand sales and marketing efforts globally.

De Novo Ventures of Palo Alto, Calif., led this round as well as SynergEyes' Series B round. Bio-Star Private Equity Fund joined Series A and B investors: Alloy Ventures, Delphi Ventures, InnoCal Venture Capital and Windward Ventures as a new investor.

SynergEyes has developed a new type of contact lens that combines two materials—a rigid gas permeable center and a soft, hydrophilic outer skirt. The result is a durable "hybrid" lens for patients seeking crisp, clear vision and the all-day comfort of a soft lens. Jim Ham, CEO for SynergEyes, Inc., said, "SynergEyes has demonstrated substantial revenue growth since market introduction in 2006. Our next-generation products will re-define state-of-the-art in the vision correction industry."

Jay Watkins, managing director of De Novo Ventures, added, "SynergEyes continues to demonstrate significant progress towards becoming a world-class vision care company. Hybrid contact lenses address a critical patient need and we are extremely pleased to continue our strong partnership with this innovative company." Renee Masi, managing member of BioStar, said, "The market potential for a product that can offer all the benefits of a rigid and soft contact lens without any of the disadvantages is tremendous."